BAFNA PHARMACEUTICALS
|
The Current P/E Ratio of BAFNA PHARMACEUTICALS is 33.84.
| Share Price | ₹138.0 | May 15,2026 |
| Market Cap | ₹327.1 Cr | |
| Earnings-TTM | ₹9.7 Cr | TTM-Standalone Results |
| Price/Earnings | 33.84x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of BAFNA PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹327.1 Cr] as on May 15,2026
(/) Earnings [ ₹9.7 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 33.84x ]
Thus, for BAFNA PHARMACEUTICALS , the investors are currently willing to pay 33.84 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BAFNA PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of BAFNA PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of BAFNA PHARMACEUTICALS
PE Ratio Performance Analysis for BAFNA PHARMACEUTICALS
- BAFNA PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 39.60x.
- BAFNA PHARMACEUTICALS 's operated at median p/e ratio of 42.73x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, BAFNA PHARMACEUTICALS 's p/e ratio peaked in Mar2022 at 57.59x.
- BAFNA PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2023 of 17.24x.
How does BAFNA PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| BAFNA PHARMACEUTICALS | 9.67 | 33.84 | 327.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 41.00 | 451,075.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 72.40 | 179,486.0 |
| CIPLA LTD | 3,869.79 | 29.88 | 115,641.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 65.64 | 149,124.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 26.93 | 111,589.0 |
| MANKIND PHARMA LTD | 1,796.65 | 57.53 | 103,368.0 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 20.62 | 101,755.0 |
| LUPIN LTD | 5,355.47 | 19.41 | 103,966.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 24.98 | 87,776.5 |
| ABBOTT INDIA LTD | 1,552.02 | 38.25 | 59,359.1 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BAFNA PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 19.41x |
| Max industry PE | 72.40x |
| Median industry PE | 33.84x |
| Average industry PE | 39.14x |
You may also like the below Video Courses